natgillin/translations-raw huggingface dataset:
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of hepatocellular carcinoma and cholangiocarcinoma according to claim 1, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is/are formulated for oral, parenteral, subcutaneous, intravenous, intramuscular, nasal, topical or rectal administration. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevu 1, naznačene time, da su nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulirane za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of hepatocellular carcinoma and cholangiocarcinoma according to claims 1 or 2, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is/are to be administered to a patient in an amount of 25 mg to 5 g, preferably 100 mg to 2,5 g, in particular 800 mg to 1,5 g per day. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevima 1 ili 2, naznačene time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, primjenjuju na pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of autoimmune hepatitis. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, naznačene time, da se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of autoimmune hepatitis according to claim 1, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is formulated for oral, parenteral, subcutaneous, intravenous, intramuscular, nasal, topical or rectal administration. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevu 1, naznačene time, da su nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, formulirane za oralnu, parenteralnu, subkutanu, intravenoznu, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu.
Nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof for use in the treatment and/or the prevention of autoimmune hepatitis according to claims 1 or 2, characterized in that nor-ursodeoxycholic acid and/or pharmaceutically acceptable salts thereof is to be administered to a patient in an amount of 25 mg to 5 g, preferably 100 mg to 2,5 g, in particular 800 mg to 1,5 g per day. 
Nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, koje se upotrebljavaju za liječenje i/ili prevenciju hepatocelularnog karcinoma i kolangiokarcinoma, prema zahtjevima 1 ili 2, naznačene time, da se nor-ursodeoksikolna kiselina i/ili njezine farmaceutski prihvatljive soli, primjenjuju na pacijentu u dnevnoj količini od 25 mg do 5 g, poželjno od 100 mg do 2,5 g, posebno od 800 mg do 1,5 g.
Device according to claim 1, characterized in that said grooved part (23) has a length chosen according to the required closing speed of said valve sector. 
Uređaj prema zahtjevu 1, naznačen time da spomenuti užljebljeni dio (23) ima dužinu koja je odabrana u skladu s potrebnom brzinom zatvaranja spomenutog ventilskog sektora.
a quantity of organic pigments, fillers, rosin modified resin and/or hydrocarbon resin and/or alkyd resin; and 
količinu organskih pigmenata, punila, kolofonijem modificiranu smolu i/ili smolu ugljikovodika i/ili alkil smolu; te
Composition for printing ink as claimed in claim 1, 2 or 3, wherein the composition comprises a quantity of ether in the range of 10-40% by weight, preferably in the range of 15-30% by weight, and most preferably about 25% by weight. 
Pripravak tinte za tiskanje prema zahtjevu 1, 2 ili 3, naznačen time da pripravak sadrži količinu etera u rasponu od 10-40% težinski, poželjno u rasponu od 15-30% težinski, te najpoželjnije od oko 25% težinski.
Composition as claimed in one or more of the foregoing claims, wherein the composition comprises a quantity of vegetal oil in the range of 2-25% by weight, and preferably about 5% by weight. 
Pripravak prema jednom ili više od prethodnih zahtjeva, naznačen time da pripravak sadrži količinu biljnog ulja u rasponu od 2-25% težinski, te poželjno oko 5% težinski.
Method for printing objects, comprising of providing a composition for printing ink as claimed in one or more of the claims 1-5. 
Postupak za ispis predmeta, naznačen time da se sastoji od osiguravanja pripravka tinte za tiskanje prema jednom ili više zahtjeva 1-5.
A frame mattress according to claim 2, characterised in that the spring inlay (3) has a zone division consisting of separate spring elements. 
Madrac s okvirom prema zahtjevu 2, naznačen time da umetak s oprugama (3) ima podjelu područja koja se sastoje od odvojenih elemenata opruga.
The pharmaceutical product of any of claims 1 to 4, wherein the first, second and third hydrophobic materials are selected from the group consisting of a cellulosic polymer, acrylic polymer and copolymer, methacrylic acid polymer and copolymers, shellac, zein, hydrogenated castor oil, hydrogenated vegetable oil, and mixtures of any of the foregoing, with the first hydrophobic material and the second hydrophobic material being preferably the same, or with the first hydrophobic material, the second hydrophobic material and the third hydrophobic material being preferably the same, or with the first hydrophobic material and the third hydrophobic material being preferably the same, or with the second hydrophobic material and the third hydrophobic material being preferably the same. 
Farmaceutski oralni dozni oblik prema zahtjevu 4, koji nadalje sadrži množinu čestica koje sadrže opioid agonist raspršen u trećem hidrofobnom materijalu. Farmaceutski oralni dozni oblik prema bilo kojem od zahtjeva 1 do 5, pri čemu prvi, drugi i/ili treći hidrofobni materijal je odabran iz skupine koja se sastoji od celuloznog polimera, akrilnog polimera i kopolimera, polimera i kopolimera metakrilne kiseline, šelaka, zeina, hidrogeniranog ricinusovog ulja, hidrogeniranog biljnog ulja, te njihovih smjesa.
The pharmaceutical product of any of claims 1 to 6, wherein the active agent is selected from the group consisting of opioid agonists, benzodiazepines, barbiturates and stimulants of the central nervous system. 
Farmaceutski oralni dozni oblik prema bilo kojem od zahtjeva 1 do 6, gdje je opioid antagonist odabran iz skupine koja se sastoji od naltreksona, naloksona, nalmefena, ciklazacina, levalorfana, njihovih farmaceutski prihvatljivih soli, ili njihovih smjesa.
A pharmaceutical composition according to claim 27, wherein the anemia is anemia incidental to chronic kidney disease. 
Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 20, gdje je anemija – anemija koja se javlja kod kronične bolesti bubrega.
A compound, pharmacologically acceptable ester thereof, or pharmacologically acceptable salt thereof according to claim 41, wherein the disease is anemia incidental to chronic kidney disease. 
Spoj, njegov farmakološki prihvatljiv ester ili njegova farmakološki prihvatljiva sol za uporabu prema patentnom zahtjevu 25, gdje je anemija – anemija koja se javlja kod kronične bolesti bubrega.
Ra and Rb each independently represent a hydrogen atom, a C1-C4 haloalkyl group, a C1-C4 hydroxyalkyl group or a linear or branched C1-C4 alkyl group; 
Ra i Rb svaki zasebno predstavljaju atom vodika, C1-C4 haloalkilnu grupu, C1-C4 hidroksialkilnu grupu ili linearnu ili razgranatu C1-C4 alkilnu grupu;
represents a group selected from: 
predstavlja grupu odabranu iz:
represents a -CR11 group and W2 represents a nitrogen atom, or W1 represents a nitrogen atom and W2 represents a -CR12 group; 
predstavlja -CR11 grupu, a W2 predstavlja atom dušika, ili W1 predstavlja atom dušika, a W2 predstavlja -CR12 grupu;
represents a linear or branched C1-C4 alkyl group, a C3-C7 cycloalkyl group, a phenyl group, a 5- to 10- membered monocyclic or bicyclic heteroaryl group containing containing one, two or three heteroatoms selected from O, S and N, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, a tetrahydropyranyl group or a morpholinyl group; 
predstavlja atom vodika, linearnu ili razgranatu C1-C4 alkilnu grupu, C1-C4 haloalkilnu grupu, C3-C7 cikloalkilnu grupu, fenilnu grupu, monocikličku ili bicikličku heteroarilnu grupu od 5 do 10 članova s jednim, dva ili tri heteroatoma odabrana iz O, S i N, pirolidinilnu grupu, piperidinilnu grupu, piperazinilnu grupu, tetrahidropiranilnu grupu ili morfolinilnu grupu;
and wherein R1 preferably represents a phenyl group or a pyridinyl group, which phenyl or pyridinyl is unsubstituted or substituted by one, two or three substituents selected from a halogen atom, a linear or branched C1-C3 alkyl group or a -(CH2)0-3OCH3 group; and wherein preferably said phenyl and pyridinyl groups are directly bonded to the pyrrolotriazinone group. 
i naznačen time, što R1 poželjnije predstavlja fenilnu grupu ili piridinilnu grupu, pri čemu je fenil ili piridinil nesupstituiran ili supstituiran s jednim, dva ili tri supstituenata odabrana iz atoma halogena, linearne ili razgranate C1-C3 alkilne grupe ili -(CH2)0-3OCH3 grupe; a naznačen time, što je poželjno da su fenilne i piridinilne grupe izravno vezane za pirolotriazinon grupu; i/ili
and wherein R3 preferably represents a hydrogen atom, a halogen atom, a hydroxy group, a C1-C3 alkoxy group, a C1-C3 haloalkyl group, a C3-C4 cycloalkyl group, a -NH2 group, a -N(CH3)H group, a -N(CH3)2 group, or a linear or branched C1-C4 alkyl group, which alkyl group is unsubstituted or substituted by a C1-C2 alkoxy group. 
i naznačen time, što R3 poželjno predstavlja atom vodika, atom halogena, hidroksilnu grupu, cijano grupu, C1-C3 alkoksi grupu, C1-C3 haloalkilnu grupu, C3-C4 cikloalkilnu grupu, -NH2 grupu, -N(CH3)H grupu, -N(CH3)2 grupu ili linearnu ili razgranatu C1-C4 alkilnu grupu, pri čemu je alkilna grupa nesupstituirana ili supstituirana C1-C2 alkoksi grupom; i/ili
and R5 together with the carbon atom to which they are attached form a pyrrolidinyl-purinyl group, wherein the purinyl group is unsubstituted or substituted by a -(CH2)0-3NR'R" group; 
i R5 zajedno s atomom ugljika za koji su vezani formiraju pirolidinil-purinilnu grupu, naznačeni time, što je purinilna grupa nesupstituirana ili supstituirana s -(CH2)0-3NR'R'' grupom;
A compound according to claim 1, which is one of: 
Spoj prema zahtjevu 1, koji je jedno od sljedećih:
A process for the purification of water and/or dewatering of sludges and/or sediments, comprising the following steps of: 
Postupak za pročišćavanje vode i/ili uklanjanje vode iz mulja i/ili taloga, koji sadrži sljedeće korake:
The process according to claim 1, wherein the water and/or sludge and/or sediment of step a) is selected from industrial waste water, drinking water, urban waste water, sludge such as harbour sludge, river sludge, coastal sludge or digested sludge, waste water or process water from breweries or other beverage industries, waste water or process water in the paper industry, colour-, paints-, or coatings industry, agricultural waste water, slaughterhouse waste water, leather industry waste water and leather tanning industry. 
Postupak prema zahtjevu 1, pri čemu su voda i/ili mulj i/ili talog iz koraka a) odabrani od industrijske otpadne vode, pitke vode, urbane otpadne vode, mulja poput lučkog mulja, riječnog mulja, obalnog mulja ili probavljenog mulja, otpadne vode ili procesne vode iz pivovara ili drugih industrija pića, otpadne vode ili procesne vode industrije papira, industrije boja, lakova ili premaza, poljoprivredne otpadne vode, otpadne vode klaonica, otpadne vode kožne industrije i industrije štavljenja kože.
The process according to any one of claims 1 to 3, wherein the source of ground calcium carbonate (GCC) is selected from marble, chalk, calcite, dolomite, limestone and mixtures thereof and/or the precipitated calcium carbonate (PCC) is selected from one or more of the aragonitic, vateritic and calcitic mineralogical crystal forms. 
Postupak prema zahtjevu 3, pri čemu je izvor mljevenog kalcij karbonata (ground calcium carbonate – GCC) odabran od mramora, krede, kalcita, dolomita, vapnenca i njihovih smjesa i/ili je istaloženi kalcij karbonat (precipitated calcium carbonate – PCC) odabran od jednog ili više od aragonitskih, vateritskih i kalcitskih mineraloških kristalnih oblika.
The process according to any one of claims 1 to 9, wherein at least 10 % of the accessible surface area of the calcium carbonate is covered by a coating comprising a cationic polymer, preferably at least 20 % of the accessible surface area, more preferably at least 30 %, even more preferably at least 40 % and most preferably at least 50 % of the accessible surface area. 
Postupak prema bilo kojem od zahtjeva 1 do 9, pri čemu je barem 10% dostupne površine kalcij karbonata prekriveno premazom koji sadrži kationski polimer, poželjno barem 20% dostupne površine, poželjnije barem 30%, još poželjnije barem 40% te najpoželjnije barem 50% dostupne površine.
The process according to claim 12, wherein the polymeric flocculation aid has a weight average molecular weight Mw in the range from 100,000 to 10,000,00 g/mole, preferably in the range from 300,000 to 5,000,000 g/mole, more preferably in the range from 300,000 to 1,000,000 g/mole and most preferably in the range from 300,000 to 800,000 g/mole and/or the polymeric flocculation aid is nonionic or ionic, preferbly a cationic or anionic polymer selected from polyacrylamides, polyacrylates, poly(diallyldimethylammonium chloride), polyethyleneimines, polyamines, starches and mixtures thereof. 
Postupak prema zahtjevu 12, pri čemu polimerni pomagač flokulacije ima prosječnu molekulsku masu Mw u rasponu od 100,000 do 10,000,00 g/mol, poželjno u rasponu od 300,000 do 5,000,000 g/mol, poželjnije u rasponu od 300,000 do 1,000,000 g/mol te najpoželjnije u rasponu od 300,000 do 800,000 g/mol i/ili je polimerni pomagač flokulacije neionski ili ionski, poželjno kationski ili anionski polimer odabran od poliakrilamida, poliakrilata, poli(dialildimetilamonij klorid), poletilenimina, poliamina, škrobova i njihovih smjesa.
The method according to claim 3, wherein the second catalyst comprises Pt on CeO2. 
Metoda u skladu s patentnim zahtjevom 3, pri čemu drugi katalizator sadrži Pt na CeO2.
said hydrocarbon is ethane; 
navedeni ugljikovodik je etan;
said first catalyst is an acidic catalyst; 
navedeni prvi katalizator je kiselinski katalizator;
glycerol is provided as a mixture with water, such as a mixture having a glycerol concentration of 15 to 30wt%; 
glicerol je priskrbljen kao smjesa s vodom, kao što je smjesa koja ima koncentraciju glicerola od 15 do 30 wt%;
the temperature of the glycerol/water-mixture when provided is 250 to 350 °C; and 
temperatura smjese glicerol/voda kada je priskrbljena iznosi 250°C do 350°C; i
The method according to claim 11, wherein said first catalyst is an acidic catalyst comprising WO3 on ZrO2. 
Metoda u skladu s patentnim zahtjevom 11, pri čemu je navedeni prvi katalizator kiselinski katalizator koji sadrži WO3 na ZrO2.
The method according to claim 1 or 8 to 10, wherein the hydrocarbon is ethene and the second catalyst is catalyst comprising Pd/CeO2 as the catalyzing specie. 
Metoda u skladu s patentnim zahtjevom 1 ili 8 do 10, pri čemu je ugljikovodik eten i drugi katalizator je katalizator koji sadrži Pd/CeO2 kao katalizirajući dio.
glycerol is provided as mixture with water in gas phase, said mixture having a temperature of 200 to 400°C; 
glicerol je priskrbljen kao smjesa s vodom u plinovitom stanju, navedena smjesa ima temperaturu od 200 do 400°C;
glycerol is converted to acrolein at a temperature of 200°C to 400°C and at a pressure of 2 to 10 bar; 
glicerol je pretvoren u akrolein na temperaturi od 200 do 400°C i kod tlaka od 2 do 10 bara;
the hydrocarbon is propane; and acrolein is converted to propane, through use of: 
ugljikovodik je propan; i akrolein je pretvoren u propan, uporabom:
a second catalyst catalyzing hydrogenation reactions, said second catalyst comprising Cu on ZnO2, to convert acrolein to propanol; 
drugog katalizatora kataliziranjem reakcije hidrogenacije, navedeni drugi katalizator sadrži Cu na ZnO2, zbog pretvorbe akrolieina u propanol;
The method according to claim 14, wherein said third catalyst comprises WO3 on ZrO2 and said fourth catalyst is a catalyst comprising a platinum group metal. 
Metoda u skladu s patentnim zahtjevom 14, pri čemu navedeni treći katalizator sadrži WO3 na ZrO2 i navedeni četvrti katalizator je katalizator koji sadrži metal iz grupe platine.
preparing a compound of formula (4), or salt thereof, wherein 
priprema spoja sa formulom (4), ili njegove soli, [image] gdje je
is hydrogen or a nitrogen protecting group; and 
vodikova ili dušikova zaštitna grupa; i
first with a base and then with a compound of the formula R4COY, wherein R4 is selected from alkyl, aryl and arylalkyl and Y is halogen or -OR', wherein R' is selected from alkyl, aryl and arylalkyl, to obtain the compound of formula (4), or salt thereof; and 
prvo sa bazom, a zatim sa spojem sa formulom R4COY, gdje je R4 odabran od alkila, arila i arilalkila a Y je halogen ili -OR', gdje je R' odabran od alkila, arila i arilalkila, kako bi se dobio spoj sa formulom (4), ili njegova sol; i
A process for preparing a compound of formula (1), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group; said process comprising the steps of 
Postupak za pripremu spoja sa formulom (1), ili njegove soli, [image] gdje je R1 vodikova ili dušikova zaštitna grupa; spomenuti postupak sadrži sljedeće korake
preparing a compound of formula (4), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group; and 
priprema spoja sa formulom (4), ili njegove soli, [image] gdje je R1 vodikova ili dušikova zaštitna grupa; i
The process according to any one of claims 1 to 8 further comprising the step of preparing N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester, or a salt thereof. 
Postupak prema bilo kojem od patentnih zahtjeva od 1 do 8 koji dalje sadrži korak pripreme etil estra N-(3-karboksil-1-oksopropil)-(4S)-(p-fenilfenilmetil)-4-amino-(2R)-metil butanske kiseline, ili njegove soli.
X is selected from F and Cl; 
X je odabran između F i Cl;
The compounds according to anyone of claims 1 to 6, for use in the prevention and/or treatment of disorders and/or diseases associated with the activity of the TRPM8 (Transient Receptor Potential cation channel subfamily M member 8),wherein said disorder and/or diseases, are selected from the group consisting of: inflammatory conditions, ischaemia, pain, urological disorders, stroke, psychiatric disorders and neurodegeneration. 
Tvari u skladu s bilo kojim od patentnih zahtjeva 1 do 6, za uporabu u prevenciji i/ili liječenju poremećaja i/ili bolesti povezanih s aktivnosti TRPM8 (prijelazni receptor potencijalnog kationskog kanala iz podobitelji M član 8, engl. Transient Receptor Potential cation channel subfamily M member 8), pri čemu su navedeni poremećaji i/ili bolesti odabrani iz grupe koja se sastoji od: upalnih stanja, ishemije, boli, uroloških poremećaja, moždanog udara, psihijatrijskih poremećaja i neurodegeneracije.
The compounds for use according to claim 7, wherein said disorder and/or diseases, are selected from chronic pain, neuropathic pain including cold allodynia and diabetic neuropathic pain, postoperative pain, osteoarthritic pain, rheumatoid arthritic pain, cancer pain, neuralgia, fibromyalgia, neuropathies, algesia, nerve injury, migraine, headaches, itch, irritable bowel syndrome and respiratory diseases, bladder syndrome, interstitial cystitis, detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperreflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, lower urinary tract disorders and lower urinary tract symptoms, anxiety and depression 
Tvari za uporabu u skladu s patentnim zahtjevom 7, pri čemu su navedeni poremećaj i/ili bolesti odabrani između kronične boli, neuropatske boli uključujući hladnu alodiniju i dijabetičku neuropatske boli, postoperativne boli, osteoartritičke boli, boli kod reumatoidnog artritisa, boli kod karcinoma, neuralgije, fibromijalgije, neuropatija, algezije, ozljede živca, migrena, glavobolja, svrbeži, sindroma iritabilnog crijeva i respiratornih bolesti, sindroma mjehura, intersticijskog cistitisa, pretjerane aktivnosti detruzora (preaktivnog mjehura), urinarne inkontinencije, neurogene pretjerane aktivnosti detruzora (hiperrefleksije detruzora), idiopatske pretjerane aktivnosti detruzora (nestabilnosti detruzora), benigne hiperplazije prostate, poremećaja donjih mokraćnih puteva i simptoma donjih mokraćnih puteva, tjeskobe i depresije
A pharmaceutical composition comprising as the active ingredient at least one compound according to any one of claims 1 to 8 in combination with suitable excipients and/or diluents. 
Farmaceutski sastav obuhvaća kao aktivni sastojak barem jednu tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 8 u kombinaciji s odgovarajućim ekscipijensima i/ili diluentima.
The pharmaceutical composition according to of claim 9 or 10, in the form of controlled release formulation. 
Farmaceutski sastav u skladu s patentnim zahtjevom 9 ili 10, u obliku formulacije s kontroliranim otpuštanjem.
oxidising the compound (IB) to obtain the compound of formula (I) having Y=SO2. 
oksidiranje tvari (IB) za dobivanje tvari formule (I) koja ima Y=SO2.
A method according to claim 2, characterised by adding a delay to a duty cycle of a closing actuator such that there is time for the bypass actuator to open before the closing actuator starts to close. 
Postupak sukladno Zahtjevu 2, naznačen dodavanjem odgode ciklusu aktuatora zatvaranja tako da ima vremena za otvaranje premosnice prije no što se aktuator zatvaranja počne zatvarati.
A method according to any one of the preceding claims, characterised by using actuators (6) with operating times of less than 10 seconds. 
Postupak sukladno bilo kojem od prethodnih Zahtjeva, naznačen korištenjem aktuatora (6) s operacijskim vremenom kraćim od 10 sekundi.
A method according to any one of the preceding claims, characterised in that a heat pump (12) is used as an energy source for the system and an internal over-pressure in the heat pump (12) is prevented by the bypass flow. 
Postupak sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što je toplinska crpka (12) upotrijebljena kao izvor energije za sustav a porast unutarnjeg pritiska u toplinskoj crpki (12) spriječen je protokom iz premosnice.
A system according to claim 7, characterised in that the operating time of the actuators (6) is less than 10 seconds. 
Sustav sukladno Zahtjevu 7, naznačen time što je operativno vrijeme aktuatora (6) manje od 10 sekundi.
A system according to claim 7 or 8, characterised in that the actuators (6) are arranged to control the flow in the heating loops (3) on and off such that during the duty cycle, the flow is high and between the duty cycles, the flow is off. 
Sustav sukladno Zahtjevu 7 ili 8, naznačen time što su aktuatori (6) organizirani na način da kontroliraju protok u petljama za zagrijavanje na način da ga otvaraju i zatvaraju tijekom radnog ciklusa kada je protok visok, tijekom radnih ciklusa protok nije omogućen.